GlassScriptPhysician profile
David M Regalla
NPI 1982661468
$1,125.01
in general payments reported to CMS, 2019-2025
19 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.99 · 2023: $43.11 · 2024: $492 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.38 | 2023-2024 | |
| Eisai INC. | $130.79 | 2024-2025 | |
| Mdd US Operations, LLC | $115.96 | 2025 | Gocovri |
| Pfizer INC. | $93.92 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $75.92 | 2024 | Rytary |
| Sk Life Science, INC. | $68.08 | 2025 | |
| Novartis Pharmaceuticals Corporation | $60.54 | 2025 | |
| Ucb, INC. | $43.00 | 2024-2025 | Rystiggo |
| Acadia Pharmaceuticals INC | $40.62 | 2024 | Nuplazid |
| Lilly USA, LLC | $40.10 | 2024-2025 | Amyvid, Kisunla |
| Genentech USA, INC. | $37.62 | 2024 | Ocrevus |
| Vanda Pharmaceuticals INC. | $28.27 | 2025 | Ponvory |
| Boston Scientific Corporation | $26.16 | 2023 | |
| Lundbeck LLC | $20.30 | 2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $19.40 | 2024 | Dysport |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.04 | 2025 | |
| Celgene Corporation | $16.92 | 2025 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $14.84 | 2021 | |
| Genzyme Corporation | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Regalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.